Related references
Note: Only part of the references are listed.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Joel C. Sunshine et al.
CLINICAL CANCER RESEARCH (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Genomic and Epigenomic Alterations in Cancer
Balabhadrapatruni V. S. K. Chakravarthi et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Unmasking PD-1 Resistance by Next-Generation Sequencing
Carlo B. Bifulco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored
Stephen K. H. Li et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Deficient mismatch repair: Read all about it
Susan Richman
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma
Jianwei Zhang et al.
MEDICAL ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
Matthew Weinstock et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
Katherine A. Hoadley et al.
CELL (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Somatic Mutations in MLH1 and MSH2 Are a Frequent Cause of Mismatch-Repair Deficiency in Lynch Syndrome-Like Tumors
Arjen R. Mensenkamp et al.
GASTROENTEROLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach
Tomio Arai et al.
GASTRIC CANCER (2013)
Comprehensive genome- and transcriptome-wide analyses of mutations associated with microsatellite instability in Korean gastric cancers
Kwiyeom Yoon et al.
GENOME RESEARCH (2013)
Immunostaining for mismatch repair (MMR) protein expression in colorectal cancer is better and easier to interpret when performed on diagnostic biopsies
Wakkas Fadhil et al.
HISTOPATHOLOGY (2012)
Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome
Christoph Engel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Microsatellite Instability Is Associated With a Better Prognosis for Gastric Cancer Patients After Curative Surgery
Wen-Liang Fang et al.
WORLD JOURNAL OF SURGERY (2012)
Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma
Fei Bao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
The Association of Tumor Microsatellite Instability Phenotype with Family History of Colorectal Cancer
Bharati Bapat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome
Patrice Watson et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Lynch syndrome in women less than 50 years of age with endometrial cancer
Kellie S. Matthews et al.
OBSTETRICS AND GYNECOLOGY (2008)
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors
Rosa M. Xicola et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers
Frank A. Sinicrope et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers
S Beghelli et al.
SURGERY (2006)
Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases
G Palmieri et al.
MELANOMA RESEARCH (2003)
Distinct clinical features and outcomes of gastric cancers with microsatellite instability
HS Lee et al.
MODERN PATHOLOGY (2002)
High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma
E Alvino et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
Share Paper
